Validation pour Ingenuity259

vers la météo de la validation par utilisateur

Ingenuity259

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 12 - PMID ?

In liver from SP , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of SP NODE mRNA that involves oral administration of NODE ( with a treatment period of 6 weeks ) .

name="reponse" value="NA"> Non annotée
name="reponse" value="JSP"> Je ne sais pas
name="reponse" value="INS"> Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

<?php echo $Com ; ?>

name="reponse" value="A0">Analyse 0

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A1">Analyse 1

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A2">Analyse 2

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A3">Analyse 3

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A4">Analyse 4

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A5">Analyse 5

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A6">Analyse 6

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A7">Analyse 7

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A8">Analyse 8

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A9">Analyse 9

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A10">Analyse 10

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A11">Analyse 11

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A12">Analyse 12

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A13">Analyse 13

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A14">Analyse 14

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A15">Analyse 15

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A16">Analyse 16

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A17">Analyse 17

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A18">Analyse 18

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A19">Analyse 19

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A20">Analyse 20

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A21">Analyse 21

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A22">Analyse 22

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A23">Analyse 23

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A24">Analyse 24

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A25">Analyse 25

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A26">Analyse 26

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A27">Analyse 27

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A28">Analyse 28

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A29">Analyse 29

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A30">Analyse 30

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A31">Analyse 31

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A32">Analyse 32

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A33">Analyse 33

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A34">Analyse 34

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A35">Analyse 35

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A36">Analyse 36

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A37">Analyse 37

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A38">Analyse 38

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A39">Analyse 39

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A40">Analyse 40

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A41">Analyse 41

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A42">Analyse 42

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A43">Analyse 43

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A44">Analyse 44

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A45">Analyse 45

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A46">Analyse 46

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A47">Analyse 47

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A48">Analyse 48

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A49">Analyse 49

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A50">Analyse 50

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A51">Analyse 51

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A52">Analyse 52

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A53">Analyse 53

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A54">Analyse 54

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A55">Analyse 55

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A56">Analyse 56

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A57">Analyse 57

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A58">Analyse 58

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A59">Analyse 59

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A60">Analyse 60

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A61">Analyse 61

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A62">Analyse 62

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A63">Analyse 63

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A64">Analyse 64

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A65">Analyse 65

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A66">Analyse 66

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A67">Analyse 67

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A68">Analyse 68

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A69">Analyse 69

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A70">Analyse 70

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A71">Analyse 71

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A72">Analyse 72

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A73">Analyse 73

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A74">Analyse 74

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A75">Analyse 75

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A76">Analyse 76

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A77">Analyse 77

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A78">Analyse 78

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A79">Analyse 79

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A80">Analyse 80

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A81">Analyse 81

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A82">Analyse 82

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A83">Analyse 83

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A84">Analyse 84

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A85">Analyse 85

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A86">Analyse 86

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A87">Analyse 87

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A88">Analyse 88

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A89">Analyse 89

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A90">Analyse 90

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A91">Analyse 91

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A92">Analyse 92

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A93">Analyse 93

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A94">Analyse 94

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A95">Analyse 95

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A96">Analyse 96

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A97">Analyse 97

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A98">Analyse 98

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A99">Analyse 99

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A100">Analyse 100

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A101">Analyse 101

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A102">Analyse 102

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A103">Analyse 103

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A104">Analyse 104

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A105">Analyse 105

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A106">Analyse 106

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A107">Analyse 107

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A108">Analyse 108

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A109">Analyse 109

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A110">Analyse 110

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A111">Analyse 111

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A112">Analyse 112

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A113">Analyse 113

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A114">Analyse 114

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A115">Analyse 115

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A116">Analyse 116

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A117">Analyse 117

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A118">Analyse 118

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A119">Analyse 119

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A120">Analyse 120

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A121">Analyse 121

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A122">Analyse 122

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A123">Analyse 123

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A124">Analyse 124

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A125">Analyse 125

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A126">Analyse 126

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A127">Analyse 127

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A128">Analyse 128

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A129">Analyse 129

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A130">Analyse 130

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A131">Analyse 131

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A132">Analyse 132

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A133">Analyse 133

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A134">Analyse 134

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A135">Analyse 135

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A136">Analyse 136

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A137">Analyse 137

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A138">Analyse 138

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A139">Analyse 139

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A140">Analyse 140

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A141">Analyse 141

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A142">Analyse 142

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A143">Analyse 143

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A144">Analyse 144

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A145">Analyse 145

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A146">Analyse 146

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A147">Analyse 147

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A148">Analyse 148

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A149">Analyse 149

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A150">Analyse 150

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A151">Analyse 151

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A152">Analyse 152

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A153">Analyse 153

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A154">Analyse 154

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A155">Analyse 155

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A156">Analyse 156

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A157">Analyse 157

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A158">Analyse 158

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A159">Analyse 159

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A160">Analyse 160

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A161">Analyse 161

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A162">Analyse 162

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A163">Analyse 163

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A164">Analyse 164

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A165">Analyse 165

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A166">Analyse 166

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A167">Analyse 167

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A168">Analyse 168

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A169">Analyse 169

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A170">Analyse 170

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A171">Analyse 171

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A172">Analyse 172

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A173">Analyse 173

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A174">Analyse 174

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A175">Analyse 175

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A176">Analyse 176

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A177">Analyse 177

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A178">Analyse 178

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A179">Analyse 179

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A180">Analyse 180

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A181">Analyse 181

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A182">Analyse 182

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A183">Analyse 183

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A184">Analyse 184

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A185">Analyse 185

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A186">Analyse 186

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A187">Analyse 187

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A188">Analyse 188

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A189">Analyse 189

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A190">Analyse 190

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A191">Analyse 191

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A192">Analyse 192

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A193">Analyse 193

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A194">Analyse 194

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A195">Analyse 195

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A196">Analyse 196

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A197">Analyse 197

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A198">Analyse 198

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A199">Analyse 199

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A200">Analyse 200

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A201">Analyse 201

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A202">Analyse 202

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A203">Analyse 203

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A204">Analyse 204

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A205">Analyse 205

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A206">Analyse 206

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A207">Analyse 207

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A208">Analyse 208

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A209">Analyse 209

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A210">Analyse 210

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A211">Analyse 211

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A212">Analyse 212

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A213">Analyse 213

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A214">Analyse 214

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A215">Analyse 215

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A216">Analyse 216

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A217">Analyse 217

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A218">Analyse 218

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A219">Analyse 219

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A220">Analyse 220

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A221">Analyse 221

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A222">Analyse 222

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A223">Analyse 223

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A224">Analyse 224

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A225">Analyse 225

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A226">Analyse 226

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A227">Analyse 227

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A228">Analyse 228

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A229">Analyse 229

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A230">Analyse 230

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A231">Analyse 231

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A232">Analyse 232

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A233">Analyse 233

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A234">Analyse 234

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A235">Analyse 235

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A236">Analyse 236

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A237">Analyse 237

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A238">Analyse 238

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A239">Analyse 239

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A240">Analyse 240

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A241">Analyse 241

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A242">Analyse 242

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A243">Analyse 243

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A244">Analyse 244

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A245">Analyse 245

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A246">Analyse 246

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A247">Analyse 247

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A248">Analyse 248

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A249">Analyse 249

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A250">Analyse 250

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A251">Analyse 251

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A252">Analyse 252

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A253">Analyse 253

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A254">Analyse 254

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A255">Analyse 255

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A256">Analyse 256

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A257">Analyse 257

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A258">Analyse 258

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A259">Analyse 259

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A260">Analyse 260

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A261">Analyse 261

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A262">Analyse 262

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A263">Analyse 263

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A264">Analyse 264

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A265">Analyse 265

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A266">Analyse 266

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A267">Analyse 267

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A268">Analyse 268

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A269">Analyse 269

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A270">Analyse 270

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A271">Analyse 271

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A272">Analyse 272

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A273">Analyse 273

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A274">Analyse 274

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A275">Analyse 275

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A276">Analyse 276

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A277">Analyse 277

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A278">Analyse 278

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A279">Analyse 279

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A280">Analyse 280

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A281">Analyse 281

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A282">Analyse 282

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A283">Analyse 283

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A284">Analyse 284

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A285">Analyse 285

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A286">Analyse 286

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A287">Analyse 287

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A288">Analyse 288

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A289">Analyse 289

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A290">Analyse 290

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A291">Analyse 291

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A292">Analyse 292

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A293">Analyse 293

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A294">Analyse 294

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A295">Analyse 295

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A296">Analyse 296

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A297">Analyse 297

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A298">Analyse 298

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A299">Analyse 299

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A300">Analyse 300

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A301">Analyse 301

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A302">Analyse 302

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A303">Analyse 303

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A304">Analyse 304

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A305">Analyse 305

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A306">Analyse 306

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A307">Analyse 307

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A308">Analyse 308

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A309">Analyse 309

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A310">Analyse 310

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A311">Analyse 311

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A312">Analyse 312

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A313">Analyse 313

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A314">Analyse 314

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A315">Analyse 315

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A316">Analyse 316

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A317">Analyse 317

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A318">Analyse 318

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A319">Analyse 319

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A320">Analyse 320

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A321">Analyse 321

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A322">Analyse 322

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A323">Analyse 323

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A324">Analyse 324

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A325">Analyse 325

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A326">Analyse 326

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A327">Analyse 327

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A328">Analyse 328

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A329">Analyse 329

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A330">Analyse 330

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A331">Analyse 331

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A332">Analyse 332

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A333">Analyse 333

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A334">Analyse 334

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A335">Analyse 335

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A336">Analyse 336

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A337">Analyse 337

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A338">Analyse 338

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A339">Analyse 339

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A340">Analyse 340

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A341">Analyse 341

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A342">Analyse 342

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A343">Analyse 343

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A344">Analyse 344

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A345">Analyse 345

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A346">Analyse 346

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A347">Analyse 347

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A348">Analyse 348

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A349">Analyse 349

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A350">Analyse 350

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A351">Analyse 351

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A352">Analyse 352

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A353">Analyse 353

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A354">Analyse 354

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A355">Analyse 355

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A356">Analyse 356

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A357">Analyse 357

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A358">Analyse 358

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A359">Analyse 359

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A360">Analyse 360

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A361">Analyse 361

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A362">Analyse 362

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A363">Analyse 363

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A364">Analyse 364

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A365">Analyse 365

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A366">Analyse 366

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A367">Analyse 367

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A368">Analyse 368

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A369">Analyse 369

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A370">Analyse 370

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A371">Analyse 371

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A372">Analyse 372

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A373">Analyse 373

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A374">Analyse 374

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A375">Analyse 375

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A376">Analyse 376

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A377">Analyse 377

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A378">Analyse 378

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A379">Analyse 379

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A380">Analyse 380

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A381">Analyse 381

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A382">Analyse 382

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A383">Analyse 383

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A384">Analyse 384

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A385">Analyse 385

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A386">Analyse 386

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A387">Analyse 387

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A388">Analyse 388

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A389">Analyse 389

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A390">Analyse 390

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A391">Analyse 391

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A392">Analyse 392

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A393">Analyse 393

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A394">Analyse 394

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A395">Analyse 395

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A396">Analyse 396

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A397">Analyse 397

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A398">Analyse 398

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A399">Analyse 399

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A400">Analyse 400

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A401">Analyse 401

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A402">Analyse 402

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A403">Analyse 403

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A404">Analyse 404

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A405">Analyse 405

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A406">Analyse 406

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A407">Analyse 407

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A408">Analyse 408

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A409">Analyse 409

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A410">Analyse 410

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A411">Analyse 411

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A412">Analyse 412

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A413">Analyse 413

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A414">Analyse 414

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A415">Analyse 415

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A416">Analyse 416

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A417">Analyse 417

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A418">Analyse 418

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A419">Analyse 419

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A420">Analyse 420

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A421">Analyse 421

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A422">Analyse 422

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A423">Analyse 423

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A424">Analyse 424

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A425">Analyse 425

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A426">Analyse 426

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A427">Analyse 427

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A428">Analyse 428

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A429">Analyse 429

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A430">Analyse 430

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A431">Analyse 431

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A432">Analyse 432

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A433">Analyse 433

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A434">Analyse 434

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A435">Analyse 435

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A436">Analyse 436

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A437">Analyse 437

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A438">Analyse 438

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A439">Analyse 439

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A440">Analyse 440

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A441">Analyse 441

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A442">Analyse 442

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A443">Analyse 443

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A444">Analyse 444

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A445">Analyse 445

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A446">Analyse 446

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A447">Analyse 447

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A448">Analyse 448

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A449">Analyse 449

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A450">Analyse 450

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A451">Analyse 451

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A452">Analyse 452

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A453">Analyse 453

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A454">Analyse 454

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A455">Analyse 455

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A456">Analyse 456

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A457">Analyse 457

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                                         +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A458">Analyse 458

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A459">Analyse 459

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A460">Analyse 460

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A461">Analyse 461

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A462">Analyse 462

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A463">Analyse 463

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A464">Analyse 464

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A465">Analyse 465

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A466">Analyse 466

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A467">Analyse 467

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A468">Analyse 468

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A469">Analyse 469

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A470">Analyse 470

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A471">Analyse 471

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A472">Analyse 472

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A473">Analyse 473

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A474">Analyse 474

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A475">Analyse 475

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A476">Analyse 476

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A477">Analyse 477

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A478">Analyse 478

                                                                                                                                                                                        +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A479">Analyse 479

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A480">Analyse 480

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A481">Analyse 481

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A482">Analyse 482

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A483">Analyse 483

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A484">Analyse 484

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A485">Analyse 485

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A486">Analyse 486

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A487">Analyse 487

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A488">Analyse 488

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A489">Analyse 489

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A490">Analyse 490

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A491">Analyse 491

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A492">Analyse 492

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A493">Analyse 493

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A494">Analyse 494

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A495">Analyse 495

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A496">Analyse 496

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A497">Analyse 497

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A498">Analyse 498

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A499">Analyse 499

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A500">Analyse 500

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A501">Analyse 501

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A502">Analyse 502

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A503">Analyse 503

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A504">Analyse 504

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A505">Analyse 505

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A506">Analyse 506

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A507">Analyse 507

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A508">Analyse 508

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A509">Analyse 509

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A510">Analyse 510

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A511">Analyse 511

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A512">Analyse 512

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A513">Analyse 513

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A514">Analyse 514

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A515">Analyse 515

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A516">Analyse 516

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A517">Analyse 517

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A518">Analyse 518

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A519">Analyse 519

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A520">Analyse 520

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A521">Analyse 521

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A522">Analyse 522

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A523">Analyse 523

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A524">Analyse 524

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A525">Analyse 525

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A526">Analyse 526

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A527">Analyse 527

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A528">Analyse 528

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A529">Analyse 529

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A530">Analyse 530

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A531">Analyse 531

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A532">Analyse 532

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A533">Analyse 533

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A534">Analyse 534

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A535">Analyse 535

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A536">Analyse 536

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A537">Analyse 537

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A538">Analyse 538

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A539">Analyse 539

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                                          |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A540">Analyse 540

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A541">Analyse 541

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A542">Analyse 542

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A543">Analyse 543

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A544">Analyse 544

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A545">Analyse 545

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A546">Analyse 546

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A547">Analyse 547

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A548">Analyse 548

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A549">Analyse 549

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A550">Analyse 550

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A551">Analyse 551

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A552">Analyse 552

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A553">Analyse 553

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A554">Analyse 554

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A555">Analyse 555

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A556">Analyse 556

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A557">Analyse 557

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A558">Analyse 558

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A559">Analyse 559

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A560">Analyse 560

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A561">Analyse 561

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A562">Analyse 562

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A563">Analyse 563

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A564">Analyse 564

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A565">Analyse 565

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A566">Analyse 566

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A567">Analyse 567

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A568">Analyse 568

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A569">Analyse 569

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A570">Analyse 570

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A571">Analyse 571

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A572">Analyse 572

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A573">Analyse 573

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A574">Analyse 574

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------------------------COMP:N-N(of)---------------------------+                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A575">Analyse 575

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A576">Analyse 576

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A577">Analyse 577

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A578">Analyse 578

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A579">Analyse 579

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A580">Analyse 580

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A581">Analyse 581

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A582">Analyse 582

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A583">Analyse 583

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A584">Analyse 584

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A585">Analyse 585

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A586">Analyse 586

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A587">Analyse 587

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A588">Analyse 588

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A589">Analyse 589

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A590">Analyse 590

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A591">Analyse 591

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A592">Analyse 592

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A593">Analyse 593

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                                                                        
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A594">Analyse 594

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A595">Analyse 595

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A596">Analyse 596

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A597">Analyse 597

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                    +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A598">Analyse 598

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A599">Analyse 599

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A600">Analyse 600

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A601">Analyse 601

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A602">Analyse 602

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A603">Analyse 603

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A604">Analyse 604

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A605">Analyse 605

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A606">Analyse 606

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                 +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A607">Analyse 607

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A608">Analyse 608

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A609">Analyse 609

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A610">Analyse 610

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A611">Analyse 611

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A612">Analyse 612

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                                                                          +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------------------COMP:N-N(of)---------------------------+                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A613">Analyse 613

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A614">Analyse 614

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A615">Analyse 615

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A616">Analyse 616

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A617">Analyse 617

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A618">Analyse 618

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A619">Analyse 619

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A620">Analyse 620

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A621">Analyse 621

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A622">Analyse 622

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A623">Analyse 623

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A624">Analyse 624

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A625">Analyse 625

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A626">Analyse 626

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A627">Analyse 627

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A628">Analyse 628

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A629">Analyse 629

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A630">Analyse 630

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A631">Analyse 631

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A632">Analyse 632

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                 +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                 |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A633">Analyse 633

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A634">Analyse 634

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A635">Analyse 635

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                                       |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A636">Analyse 636

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A637">Analyse 637

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A638">Analyse 638

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                    +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+                 |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                 |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+COMP:N-N+        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,5)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A639">Analyse 639

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           +----------------------COMP:V-N(with)----------------------+                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
COMP:V-N(with) (involve,period)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A640">Analyse 640

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A641">Analyse 641

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A642">Analyse 642

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  |                                                                                                                              
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A643">Analyse 643

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A644">Analyse 644

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A645">Analyse 645

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A646">Analyse 646

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      +----------------------------COMP:N-N(of)---------------------------+                                                                                                  +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,carboxamide)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A647">Analyse 647

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A648">Analyse 648

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A649">Analyse 649

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A650">Analyse 650

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A651">Analyse 651

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
                                                                                                                                                                             |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A652">Analyse 652

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                                       +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+----------COMP:N-N(of)----------+          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
COMP:N-N(of) (injection,carboxamide)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A653">Analyse 653

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A654">Analyse 654

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                           |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A655">Analyse 655

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A656">Analyse 656

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+                                                                      |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A657">Analyse 657

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A658">Analyse 658

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A659">Analyse 659

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |                          +COMP:N-N(o+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |                 +MOD_ATT:+      +MOD+      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |                 |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,6)

name="reponse" value="A660">Analyse 660

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      +----------------COMP:N-N(of)---------------+        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
COMP:N-N(of) (liver,5)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A661">Analyse 661

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                                                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                                                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+                       +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A662">Analyse 662

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A663">Analyse 663

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A664">Analyse 664

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A665">Analyse 665

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A666">Analyse 666

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A667">Analyse 667

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A668">Analyse 668

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+-------------------------APPOS------------------------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
APPOS (ribofuranoside,period)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A669">Analyse 669

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A670">Analyse 670

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      |                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A671">Analyse 671

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A672">Analyse 672

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A673">Analyse 673

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A674">Analyse 674

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A675">Analyse 675

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                                                   |                      +----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A676">Analyse 676

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A677">Analyse 677

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A678">Analyse 678

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A679">Analyse 679

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A680">Analyse 680

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+                                                                                                                              
      |                                  |                                |                      |                   +-----------COMP:N-N(of)-----------+                    |                                                                                                                              
      |                                  |                                |                      |                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A681">Analyse 681

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A682">Analyse 682

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A683">Analyse 683

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                                                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A684">Analyse 684

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A685">Analyse 685

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A686">Analyse 686

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |                                +-------------------------------------------COMP:V-N(of)-------------------------------------------+                                                                                                                              
      |                                  |                                |                      +----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |                                |                      |                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A687">Analyse 687

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |                                              +----------------------------------SUBJ:V-N---------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                   +-----------COMP:N-N(of)-----------+                    |          +---------------SUBJ:V-N---------------+                               |                                            
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   |          +-----------COMP:N-N(of)-----------+         |          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   |          |                       +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (00.5mg/g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A688">Analyse 688

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                           |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A689">Analyse 689

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A690">Analyse 690

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+----------------------------------SUBJ:V-N---------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+                   +-----------------COMP:N-N(of)----------------+         |          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+          |         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A691">Analyse 691

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A692">Analyse 692

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A693">Analyse 693

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                           +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                                            
      |                                           |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                                            
      +----------COMP:N-N(from)----------+        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A694">Analyse 694

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+                                                                                                                              
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+                                                                                                                              
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |                                                                                                                              
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+----------------COMP:N-N(of)---------------+                                            
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+--SUBJ:V-N-+      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(of) (mRNA,__NODE__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A695">Analyse 695

                                                                                                                                                                             +-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                                                   +-------------------------------------------COMP:V-N(of)-------------------------------------------+          +---------------SUBJ:V-N---------------+                               |                          |                 
      +----------COMP:N-N(from)----------+                                |                      +----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+                                |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+                 +--MOD_ATT:N-N-+          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |                 |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
COMP:N-N(from) (liver,injection)
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (carboxamide,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(of) (decrease,carboxamide)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-ADJ (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)

name="reponse" value="A696">Analyse 696

      +-----------------------------------------------------------------------------COMP:V-N(In)-----------------------------------------------------------------------------+                                                                                                                              
      |                                  +-----------------------------------------------------------COMP:V-N(from)----------------------------------------------------------+-----------------------------------------------COMP:V-N(with)-----------------------------------------------+                 
      |                                  |        +-------------------------------------------------------COMP:V-N(of)-------------------------------------------------------+          +-----------------------------COMP:N-N(of)-----------------------------+                          |                 
      |                                  |        |        +-------------MOD_ATT:N-N-------------+                                                                           |          +---------------SUBJ:V-N---------------+                               |                          |                 
      |                                  |        |        |              +------MOD_ATT:N-N-----+----------------------------------SUBJ:V-N---------------------------------+          +-------COMP:N-N(of)-------+           |                               |                          |                 
      |           +-----MOD_ATT:N-ADJ----+        |        |              |          +MOD_ATT:N-N+                   +-----------COMP:N-N(of)-----------+COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ+           +-----OBJ:V-N----+              |        +-----------OBJ:V-N----------+      
      |           |           +MOD_ATT:N-+        |        |              |          |  +MOD_ATT:+                   +COMP:N-N(o+              +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_AT+           |      +MOD_ATT:N+              |        |        +MOD_ATT:+COMP:N+   |      
      |           |           |          |        |        |              |          |  |        |                   |          |              |        |      |   |         |          |           |       |      |           |      |         |              |        |        |        |      |   |      
 In liver from __SP__ , subcutaneous injection of 5 aminoimidazole 4 carboxamide 1 beta D ribofuranoside ( with a dosage of 00.5mg/g and a treatment period of 3 weeks ) decreases expression of __SP__ __NODE__ mRNA that involves oral administration of __NODE__ ( with a treatment period of 6 weeks ) .
MOD_ATT:N-ADJ (injection,__SP__)
MOD_ATT:N-ADJ (injection,subcutaneous)
MOD_ATT:N-N (ribofuranoside,aminoimidazole)
MOD_ATT:N-N (ribofuranoside,carboxamide)
MOD_ATT:N-N (ribofuranoside,beta)
MOD_ATT:N-N (ribofuranoside,D)
COMP:N-N(of) (dosage,00.5mg/g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,3)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,injection)
COMP:V-N(of) (decrease,5)
SUBJ:V-N (decrease,ribofuranoside)
OBJ:V-N (decrease,expression)
COMP:V-N(with) (decrease,period)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,administration)
MOD_ATT:N-N (administration,oral)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,6)